We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

SCHW:NYSECharles Schwab Corporation (The) Analysis

Data as of 2026-03-09 - not real-time

$94.38

Latest Price

5/10Risk

Risk Level: Medium

Executive Summary

SCHW is trading just above its 20‑day simple moving average while the 20‑day SMA sits slightly below the market price, suggesting limited upside momentum. The 14‑day RSI is in the low‑40s, indicating the stock is not overbought nor oversold, and the MACD histogram is positive, giving a modest bullish signal despite a neutral overall trend. Volatility over the past 30 days is high at roughly 33%, but the beta of under 1 points to lower systematic risk than the market, and the Fear & Greed Index shows “Extreme Greed,” implying bullish sentiment may be overstretched. The dividend yield of about 1.3% with a modest payout ratio under 25% supports a sustainable income stream. Fundamentally, revenue grew nearly 19% YoY, margins remain exceptionally high, and cash balances dwarf total debt, creating a strong balance‑sheet cushion. The discounted cash‑flow model values SCHW near $133, implying a sizable discount to the current price and an upside potential of roughly 28% versus analyst targets. Recent client‑asset growth of 18% YoY and net new assets of $27.8 billion underscore the firm’s growth engine. Analyst consensus remains a “Buy,” reinforcing the undervalued narrative.

Market Outlook

Short Term

< 1 year
Positive
Model confidence: 7/10

Key Factors

  • Technical support near current price
  • Positive MACD histogram
  • Sustainable dividend

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • Strong revenue growth and high margins
  • Robust cash position relative to debt
  • Analyst consensus and target price upside

Long Term

> 3 years
Positive
Model confidence: 9/10

Key Factors

  • Continued client‑asset inflows
  • Undervalued DCF fair value
  • Stable dividend with low payout ratio

Key Metrics & Analysis

Financial Health

Revenue Growth18.90%
Profit Margin37.00%
P/E Ratio20.3
ROE18.10%
ROA1.82%
Debt/Equity115.32
P/B Ratio3.9
Op. Cash Flow$9.3B
Industry P/E17.4

Technical Analysis

TrendNeutral
RSI42.1
Support$91.28
Resistance$107.50
MA 20$95.64
MA 50$99.77
MA 200$95.10
MACDBullish
VolumeDecreasing
Fear & Greed Index100

Valuation

Fair Value$133.07
Target Price$120.68
Upside/Downside27.87%
GradeUndervalued
TypeGrowth
Dividend Yield1.34%

Risk Assessment

Beta0.84
Volatility33.02%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.